JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
JOHNSON & JOHNSON
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026
$253.79−1.77 (-0.69%)
Close on Oct 19, 2026
- Market cap
- $619.27B
- P/E (TTM)
- 29.4
- Dividend yield
- 2.03%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
74.7%
1.80B of 2.41B shares
Institutional holders
4,673
222 new, 119 sold out
Net institutional buying
42M
In Q2 2026
Insider trades, 12 months
1 buys · 28 sales
Net sold $150.41M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 186,308,341 | 7.70% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 180,631,228 | 7.49% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | – | 5.52% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of JNJ | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 212,098,264 | 8.80% | $53.87B | −1,287,282 | 0.80% |
| Vanguard Capital Management LLC | 157,226,374 | 6.52% | $39.93B | +621,004 | 0.85% |
| State Street Corp | 133,776,025 | 5.55% | $33.98B | +299,737 | 1.01% |
| Vanguard Portfolio Management LLC | 64,370,816 | 2.67% | $16.35B | +856,380 | 0.74% |
| Geode Capital Management, LLC | 59,086,417 | 2.45% | $14.97B | −78,445 | 0.80% |
| JPMorgan Chase & Co | 58,301,609 | 2.42% | $15.07B | −4,794,735 | 0.83% |
| Morgan Stanley | 44,808,254 | 1.86% | $11.38B | +87,087 | 0.60% |
| Norges Bank | 31,825,084 | 1.32% | $8.08B | New | 0.81% |
| State Farm Mutual Automobile Insurance Co | 31,590,952 | 1.31% | $8.02B | – | 5.49% |
| Northern Trust Corp | 28,792,064 | 1.19% | $7.31B | −527,605 | 0.85% |
| Bank Of America Corp /De/ | 23,438,141 | 0.97% | $5.95B | −2,078,556 | 0.38% |
| Price T Rowe Associates Inc /Md/ | 22,996,878 | 0.95% | $5.84M | +6,505,745 | 0.58% |
| FMR LLC | 22,595,566 | 0.94% | $5.74B | −2,176,262 | 0.25% |
| Wellington Management Group Llp | 22,588,696 | 0.94% | $5.74B | +2,513,321 | 0.99% |
| Bank of New York Mellon Corp | 21,683,347 | 0.90% | $5.51B | −138,615 | 0.90% |
| Goldman Sachs Group Inc | 19,722,544 | 0.82% | $5.01B | +1,665,497 | 0.43% |
| Legal & General Group Plc | 19,286,904 | 0.80% | $4.90B | −60,958 | 1.02% |
| Charles Schwab Investment Management Inc | 19,126,165 | 0.79% | $4.86B | −51,054 | 0.65% |
| UBS Asset Management Americas Inc | 18,416,123 | 0.76% | $4.68B | −1,211,990 | 0.85% |
| Wells Fargo & Company/Mn | 17,374,433 | 0.72% | $4.41B | +448,979 | 0.71% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 4,673 | 1.80B | 74.7% | 222 / 2052 | 1908 / 119 | 103M | 61M |
| Q1 2026 | 4,647 | 1.78B | 73.7% | 302 / 1712 | 2161 / 124 | 344M | 113M |
| Q4 2025 | 4,539 | 1.79B | 74.3% | 543 / 1654 | 1935 / 106 | 129M | 129M |
| Q3 2025 | 4,196 | 1.80B | 74.6% | 295 / 1704 | 1800 / 120 | 134M | 105M |
| Q2 2025 | 4,092 | 1.77B | 73.5% | 176 / 1635 | 1889 / 181 | 81M | 50M |
| Q1 2025 | 4,157 | 1.74B | 72.4% | 255 / 1707 | 1842 / 147 | 92M | 77M |
| Q4 2024 | 4,112 | 1.74B | 72.3% | 470 / 1357 | 1937 / 177 | 93M | 95M |
| Q3 2024 | 3,891 | 1.76B | 72.8% | 230 / 1559 | 1735 / 104 | 267M | 48M |
| Q2 2024 | 3,811 | 1.74B | 72.1% | 161 / 1517 | 1791 / 153 | 84M | 137M |
| Q1 2024 | 3,857 | 1.80B | 74.7% | 163 / 1573 | 1752 / 128 | 109M | 54M |
| Q4 2023 | 3,875 | 1.75B | 72.6% | 378 / 1303 | 1881 / 126 | 133M | 49M |
| Q3 2023 | 3,684 | 1.67B | 69.2% | 151 / 1222 | 2004 / 181 | 29M | 175M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of JNJ | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 76,421,624 | 3.17% | $19.41B | 0.84% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 62,378,802 | 2.59% | $15.84B | 0.95% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 33,111,750 | 1.37% | $8.41B | 0.95% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 30,839,534 | 1.28% | $6.95B | 0.84% | May 31, 2026 |
| Vanguard Value Index Fund | 22,911,023 | 0.95% | $5.82B | 2.29% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 17,006,170 | 0.71% | $4.32B | 10.64% | Jun 30, 2026 |
| Vanguard Dividend Appreciation Index Fund | 13,619,903 | 0.57% | $3.49B | 2.67% | Jul 31, 2026 |
| Vanguard Institutional Index Fund | 13,067,915 | 0.54% | $3.32B | 0.95% | Jun 30, 2026 |
| Vanguard High Dividend Yield Index Fund | 9,702,127 | 0.40% | $2.49B | 2.51% | Jul 31, 2026 |
| Washington Mutual Investors Fund | 9,490,561 | 0.39% | $2.43B | 1.12% | Jul 31, 2026 |
| Vanguard Health Care Fund | 7,191,566 | 0.30% | $1.84B | 4.83% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 7,135,556 | 0.30% | $1.61B | 8.47% | May 31, 2026 |
| Columbia Dividend Income Fund | 7,113,980 | 0.30% | $1.60B | 3.40% | May 31, 2026 |
| JPMorgan Large Cap Growth Fund | 6,791,600 | 0.28% | $1.72B | 1.42% | Jun 30, 2026 |
| MFS Value Fund | 6,243,503 | 0.26% | $1.41B | 2.75% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joaquin Duato | CEO and Chairman of the Board, Director | 307,837 | 0.01% | Aug 14, 2026 |
| Timothy Schmid | EVP, WW Chair, MedTech | 48,778 | 0.00% | Sep 4, 2026 |
| Thomas Cavanaugh | EVP WW Chair, Innovative Med. | 499 | 0.00% | Sep 1, 2026 |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | 209,451 | 0.01% | Aug 18, 2026 |
| Elizabeth Forminard | EVP, Chief Legal Officer | 23,568 | 0.00% | Aug 7, 2026 |
| Vanessa Broadhurst | EVP, Global Corp Affairs | 23,003 | 0.00% | Jul 21, 2026 |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | 124,659 | 0.01% | Jun 12, 2026 |
| John C. Reed | EVP, Innovative Medicine, R&D | 35,913 | 0.00% | May 4, 2026 |
| Robert J. Decker | VP Corporate Controller | 28,537 | 0.00% | Mar 3, 2026 |
| Joseph J. Wolk | Exec VP, CFO | 109,969 | 0.00% | Feb 18, 2026 |
| James D. Swanson | EVP, CIO | 46,219 | 0.00% | Feb 18, 2026 |
| Kristen Mulholland | EVP, Chief HR Officer | 19,678 | 0.00% | Feb 18, 2026 |
| Eugene A. Woods | Director | 250 | 0.00% | Sep 10, 2026 |
| Marillyn A. Hewson | Director | 3,000 | 0.00% | Sep 10, 2026 |
| Daniel E. Pinto | Director | 0 | – | Sep 10, 2026 |
| John G. Morikis | Director | 1,849 | 0.00% | Apr 27, 2026 |
| Hubert Joly | Director | 5,000 | 0.00% | Apr 27, 2026 |
| Mark B. McClellan | Director | – | – | Apr 27, 2026 |
| Mary C. Beckerle | Director | – | – | Apr 27, 2026 |
| Mark A. Weinberger | Director | 1,000 | 0.00% | Apr 27, 2026 |
| Paula A. Johnson | Director | 191 | 0.00% | Apr 27, 2026 |
| Nadja West | Director | – | – | Apr 27, 2026 |
| Jennifer A. Doudna | Director | – | – | Apr 27, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Timothy Schmid EVP, WW Chair, MedTech | Sep 2, 2026 | Option exercise | +22,527 | $151.41 | $3.41M | 47,974 |
| Timothy Schmid EVP, WW Chair, MedTech | Sep 2, 2026 | Option exercise | +11,070 | $131.94 | $1.46M | 36,517 |
| Timothy Schmid EVP, WW Chair, MedTech | Sep 2, 2026 | Sale | −11,070 | $274.74 | $3.04M | 25,447 |
| Timothy Schmid EVP, WW Chair, MedTech | Sep 2, 2026 | Sale | −22,527 | $274.74 | $6.19M | 25,447 |
| Jennifer L. Taubert EVP, WWC. Innovative Medicine | Aug 17, 2026 | Option exercise | +15,000 | $115.67 | $1.74M | 209,451 |
| Jennifer L. Taubert EVP, WWC. Innovative Medicine | Aug 17, 2026 | Sale | −15,000 | $263.36 | $3.95M | 194,451 |
| Joaquin Duato CEO and Chairman of the Board, Director | Aug 13, 2026 | Sale | −102,315 | $261.00 | $26.70M | 275,967 |
| Joaquin Duato CEO and Chairman of the Board, Director | Aug 13, 2026 | Option exercise | +123,291 | $115.67 | $14.26M | 399,258 |
| Joaquin Duato CEO and Chairman of the Board, Director | Aug 13, 2026 | Sale | −20,976 | $262.00 | $5.50M | 378,282 |
| Elizabeth Forminard EVP, Chief Legal Officer | Aug 6, 2026 | Sale | −9,344 | $257.76 | $2.41M | 23,568 |
| Elizabeth Forminard EVP, Chief Legal Officer | Aug 6, 2026 | Option exercise | +9,344 | $131.94 | $1.23M | 32,912 |
| Elizabeth Forminard EVP, Chief Legal Officer | Aug 6, 2026 | Sale | −6,574 | $255.93 | $1.68M | 16,994 |
| Joaquin Duato CEO and Chairman of the Board, Director | Aug 5, 2026 | Sale | −6,523 | $258.74 | $1.69M | 275,967 |
| Joaquin Duato CEO and Chairman of the Board, Director | Aug 5, 2026 | Sale | −41,957 | $258.06 | $10.83M | 282,490 |
| Vanessa Broadhurst EVP, Global Corp Affairs | Jul 20, 2026 | Sale | −23,054 | $251.27 | $5.79M | 23,003 |
| Vanessa Broadhurst EVP, Global Corp Affairs | Jul 20, 2026 | Option exercise | +11,925 | $131.94 | $1.57M | 46,057 |
| Vanessa Broadhurst EVP, Global Corp Affairs | Jul 20, 2026 | Option exercise | +11,129 | $129.51 | $1.44M | 34,132 |
| Kathryn E. Wengel EVP, Chief TO and Risk Officer | Jun 11, 2026 | Option exercise | +10,000 | $115.67 | $1.16M | 124,288 |
| Kathryn E. Wengel EVP, Chief TO and Risk Officer | Jun 11, 2026 | Sale | −10,000 | $241.15 | $2.41M | 114,288 |
| John C. Reed EVP, Innovative Medicine, R&D | May 1, 2026 | Option exercise | +25,255 | – | – | 35,913 |
| John C. Reed EVP, Innovative Medicine, R&D | May 1, 2026 | Tax withholding | −11,002 | $229.85 | $2.53M | 24,911 |
| Robert J. Decker VP Corporate Controller | Feb 27, 2026 | Option exercise | +4,075 | $115.67 | $471.36K | 27,757 |
| Robert J. Decker VP Corporate Controller | Feb 27, 2026 | Sale | −4,075 | $247.87 | $1.01M | 23,682 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 20, 2026 | Sale | −1,322 | $245.66 | $324.76K | 25,447 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 18, 2026 | Option exercise | +13,625 | $115.67 | $1.58M | 40,394 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 18, 2026 | Sale | −13,625 | $244.20 | $3.33M | 26,769 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 18, 2026 | Option exercise | +8,998 | $129.51 | $1.17M | 35,767 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 18, 2026 | Sale | −8,998 | $244.53 | $2.20M | 26,769 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 17, 2026 | Option exercise | +21,721 | $157.92 | $3.43M | 34,662 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 17, 2026 | Sale | −21,721 | $243.00 | $5.28M | 12,941 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 17, 2026 | Sale | −2,283 | $243.00 | $554.77K | 10,658 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 17, 2026 | Sale | −29,927 | $243.00 | $7.27M | 12,941 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 17, 2026 | Option exercise | +29,927 | $156.15 | $4.67M | 42,868 |
| Joseph J. Wolk Exec VP, CFO | Feb 17, 2026 | Sale | −12,066 | $242.87 | $2.93M | 38,961 |
| Joseph J. Wolk Exec VP, CFO | Feb 17, 2026 | Option exercise | +33,386 | $131.94 | $4.40M | 72,347 |
| Joseph J. Wolk Exec VP, CFO | Feb 17, 2026 | Sale | −33,386 | $242.75 | $8.10M | 38,961 |
| Joseph J. Wolk Exec VP, CFO | Feb 17, 2026 | Sale | −24,961 | $242.68 | $6.06M | 14,000 |
| Joseph J. Wolk Exec VP, CFO | Feb 17, 2026 | Sale | −19,241 | $242.99 | $4.68M | 38,961 |
| Joseph J. Wolk Exec VP, CFO | Feb 17, 2026 | Option exercise | +19,241 | $115.67 | $2.23M | 58,202 |
| Joseph J. Wolk Exec VP, CFO | Feb 17, 2026 | Option exercise | +12,066 | $129.51 | $1.56M | 51,027 |
| Vanessa Broadhurst EVP, Global Corp Affairs | Feb 17, 2026 | Sale | −6,197 | $243.39 | $1.51M | 23,003 |
| James D. Swanson EVP, CIO | Feb 17, 2026 | Option exercise | +20,521 | $164.62 | $3.38M | 46,219 |
| James D. Swanson EVP, CIO | Feb 17, 2026 | Sale | −20,521 | $242.70 | $4.98M | 25,698 |
| Elizabeth Forminard EVP, Chief Legal Officer | Feb 15, 2026 | Option exercise | +961 | – | – | 23,541 |
| Elizabeth Forminard EVP, Chief Legal Officer | Feb 15, 2026 | Tax withholding | −492 | $243.45 | $119.78K | 23,049 |
| Elizabeth Forminard EVP, Chief Legal Officer | Feb 15, 2026 | Option exercise | +1,063 | – | – | 24,112 |
| Elizabeth Forminard EVP, Chief Legal Officer | Feb 15, 2026 | Tax withholding | −544 | $243.45 | $132.44K | 23,568 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 15, 2026 | Tax withholding | −385 | $243.45 | $93.73K | 11,622 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 15, 2026 | Tax withholding | −528 | $243.45 | $128.54K | 12,941 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 15, 2026 | Option exercise | +1,847 | – | – | 13,469 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 15, 2026 | Option exercise | +1,349 | – | – | 12,007 |
| Jennifer L. Taubert EVP, WWC. Innovative Medicine | Feb 15, 2026 | Tax withholding | −945 | $243.45 | $230.06K | 194,451 |
| Jennifer L. Taubert EVP, WWC. Innovative Medicine | Feb 15, 2026 | Option exercise | +1,847 | – | – | 195,396 |
| Jennifer L. Taubert EVP, WWC. Innovative Medicine | Feb 15, 2026 | Tax withholding | −816 | $243.45 | $198.66K | 193,549 |
| Jennifer L. Taubert EVP, WWC. Innovative Medicine | Feb 15, 2026 | Option exercise | +1,594 | – | – | 194,365 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 15, 2026 | Option exercise | +1,028 | – | – | 26,206 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 15, 2026 | Tax withholding | −15 | $243.45 | $3.65K | 26,191 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 15, 2026 | Option exercise | +1,026 | – | – | 27,217 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 15, 2026 | Tax withholding | −448 | $243.45 | $109.07K | 26,769 |
| Joaquin Duato CEO and Chairman of the Board, Director | Feb 15, 2026 | Option exercise | +4,505 | – | – | 326,407 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Timothy Schmid Officer | Sep 2, 2026 | 33,597 | $9.23M | Sep 2, 2026 | Stock Option Exercise |
| Jennifer L. Taubert Officer | Aug 17, 2026 | 15,000 | $3.95M | Aug 17, 2026 | Stock Option Exercise |
| Joaquin Duato Officer, Director | Aug 13, 2026 | 123,291 | $32.20M | Aug 13, 2026 | Stock Option Exercise |
| Elizabeth Forminard Officer | Aug 6, 2026 | 15,918 | $4.09M | Aug 6, 2026 | Stock Option Exercise |
| Duato Joaquin CEO, Chariman | Aug 5, 2026 | 48,480 | $12.36M | Aug 5, 2026 | Executive compensation |
| Vanessa Broadhurst Officer | Jul 20, 2026 | 23,054 | $5.79M | Jul 20, 2026 | Stock Option Exercise |
| Kathryn E. Wengel Officer | Jun 11, 2026 | 10,000 | $2.40M | Jun 11, 2026 | Stock Option Exercise |
| Robert J. Decker Officer | Feb 27, 2026 | 4,075 | $1.01M | Feb 27, 2026 | Option Granted - 02/13/2017 |
| Timothy Schmid Officer | Feb 20, 2026 | 1,322 | $324.76K | Feb 20, 2026 | Restricted Stock Vesting |
| Timothy Schmid Officer | Feb 18, 2026 | 22,623 | $5.53M | Feb 18, 2026 | Option Granted - 02/13/2017 |
| Vanessa Broadhurst Officer | Feb 17, 2026 | 6,197 | $1.51M | Feb 17, 2026 | Restricted Stock Vesting |
| James D. Swanson Officer | Feb 17, 2026 | 20,521 | $4.98M | Feb 17, 2026 | Options Granted - 02/08/2021 |
| Joseph J. Wolk Officer | Feb 17, 2026 | 89,654 | $21.77M | Feb 17, 2026 | Restricted Stock Vesting |
| John C. Reed Officer | Feb 17, 2026 | 53,931 | $13.11M | Feb 17, 2026 | Restricted Stock Vesting |
| James D. Swanson Officer | Feb 13, 2026 | 41,559 | $10.13M | Feb 13, 2026 | Option Granted - 02/14/2022 |